CBS (cystathione beta synthase) is a fairly common single nucleuotide polymorphism, and can result in increased expression of HIF-2 alpha thus increasing tumorogenesis. Treatment with antiangiogenics block expression of VEGF. Would the presence of the upregulated HIF-2 change the efficacy of the VEGF inhibitor and weaken tumor response?